New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients

For media outside of the U.S.A. only

Key data from Boehringer Ingelheim´s hepatitis C virus (HCV) clinical trial programme, HCVersoTM, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities. These data are one of five abstracts from a range of new Boehringer Ingelheim HCV data that have been accepted for presentation at the International Liver Congress (ILC)TM 2012, taking place 18th "´ 22nd April in Barcelona, Spain.

Boehringer Ingelheim´s accepted abstracts not included in EASL media activities can be accessed through the EASL website today, www.easl.eu. The Boehringer Ingelheim data included in EASL media activities will remain under embargo until the time of presentation on 21st April. All Boehringer Ingelheim´s data presentations are listed below.

Collectively, these data underscore the company´s focus on finding answers to the challenges faced by HCV patients.

Selected for oral presentation and inclusion in official EASL press office activities:

SOUND-C2 interim results: SVR4 and SVR12
with an interferon-free regimen of BI
201335 and BI 207127 +/- ribavirin, in
treatment-naive patients with chronic
genotype-1 HCV infection

Oral abstract presentation
Date: Sat, 21st April
Time: 8:30 "´ 8:45 a.m. CEST

Poster presentations "´ abstracts available online currently:

SOUND-C2 interim analysis: The efficacy
and safety of the interferon-free
combination of BI 201335 and BI 207127 in
genotype-1 HCV patients with cirrhosi

Late breaker poster#: 1420
Date: Thurs, 19th April
Time: 12:00-1:30 p.m. CEST

Characterization of HCV NS3 variants that
emerged during virologic breakthrough and
relapse from BI 201335 Phase 2 SILEN-C2
study in pegylated-interferon plus
ribavirin treatment-experienced patient

Poster#: 1185
Date: Sat, 21st April
Time: 12:30 "´ 1:30 p.m. CEST

Impact of early response definitions on
duration and outcome of treatment with BI
201335 plus pegylated-interferon plus
ribavirin

Poster#: 1209
Date: Sat 21st April
Time: 12:30 "´ 1:30 p.m. CEST

Preclinical characterization of the
hepatitis C virus NS5B polymerase
non-nucleoside inhibitor BI 207127

P. Beaulieu

Poster#: 822
Date: Fri, 20th April
Time: 12:30 "´ 2:00 p.m. CEST

Boehringer Ingelheim is continuing to support its aim of delivering a simpler HCV cure for all patients, including those toughest to treat through the company´s rigorous clinical trial programme; HCVersoTM.

For more information on Boehringer Ingelheim´s HCV portfolio, please visit www.boehringer-ingelheim.com and follow the company on Twitter www.twitter.com/boehringer.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world´s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Within the company´s global research network, Virology is one of the seven R&D areas with focus on Hepatitis C.

In 2010, Boehringer Ingelheim posted net sales of while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.